← Back to Search

Antibiotic

Rifaximin for Hepatic Encephalopathy (RED-C-3132 Trial)

Phase 3
Waitlist Available
Research Sponsored by Bausch Health Americas, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥ 18 and ≤ 85 years of age
Be older than 18 years old
Must not have
Active COVID-19 that is unresolved
History of SBP
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

This trial tests if rifaximin, an oral antibiotic, can delay brain problems in patients with liver cirrhosis and controlled fluid buildup by reducing harmful gut bacteria. Rifaximin has been shown to reduce the recurrence of brain-related issues and related hospitalizations.

Who is the study for?
This trial is for adults aged 18-85 with liver cirrhosis and controlled fluid buildup in the abdomen. Participants must have a clear mental state (MMSE score >24) and no severe brain dysfunction (Conn score <2). Those with recent serious infections, internal bleeding, kidney issues, or past overt hepatic encephalopathy are excluded.
What is being tested?
The study compares Rifaximin SSD-40mg IR against a placebo to see if it can delay the first episode of overt hepatic encephalopathy—a severe liver-related brain disorder—in patients with liver cirrhosis. It's randomized and double-blind, meaning neither doctors nor patients know who gets the real treatment.
What are the potential side effects?
Potential side effects of Rifaximin may include abdominal pain, nausea, dizziness, fatigue, peripheral edema (swelling), anemia (low red blood cell count), rash or itching. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I currently have COVID-19.
Select...
I have a history of spontaneous bacterial peritonitis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Rifaximin SSD-40mg IRExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rifaximin SSD
2015
Completed Phase 2
~20

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for encephalopathy, such as Rifaximin SSD-40mg IR, primarily work by altering gut microbiota and reducing ammonia production. Rifaximin is a non-absorbable antibiotic that targets gut bacteria responsible for producing ammonia, a neurotoxin that can exacerbate encephalopathy. By reducing the population of these bacteria, Rifaximin lowers ammonia levels in the blood, thereby alleviating symptoms. This mechanism is crucial for encephalopathy patients as it directly addresses one of the primary causes of their condition, leading to improved cognitive function and quality of life.

Find a Location

Who is running the clinical trial?

Bausch Health Americas, Inc.Lead Sponsor
262 Previous Clinical Trials
81,450 Total Patients Enrolled
Michael MaderStudy DirectorBausch Health
1 Previous Clinical Trials
466 Total Patients Enrolled
John LaheyStudy DirectorBausch Health
5 Previous Clinical Trials
998 Total Patients Enrolled

Media Library

Rifaximin SSD (Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT05297448 — Phase 3
Encephalopathy Research Study Groups: Placebo, Rifaximin SSD-40mg IR
Encephalopathy Clinical Trial 2023: Rifaximin SSD Highlights & Side Effects. Trial Name: NCT05297448 — Phase 3
Rifaximin SSD (Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05297448 — Phase 3
~140 spots leftby Jan 2026